GeneDx WGS · Analysis & News
Heads-up: USD CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI n.s.a. m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
GeneDx lands in neutral territory: solid third-quarter revenue and maintained full-year guidance are offset by trimmed growth targets and a wider net loss. No price history is available for WGS, so the verdict rests on the earnings picture alone.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for GeneDx Holdings
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Q3 2026 revenue rose to $123.1M from $116.7M a year earlier.
- Full-year revenue guidance was maintained at $475-490M with adjusted net income of about $12M.
- Adjusted gross margin guidance was lifted to approximately 71 percent.
What argues against it
- Growth targets were trimmed: exome and genome volumes to at least 28%, exome revenue growth to at least 17%.
- The reported net loss widened to $12.3M from $7.6M, and operating cash flow was negative at $72.0M.
- High-impact US inflation readings due shortly are event risk for the broader market and the stock.
What would change the picture
- A clear beat or miss on the lowered exome and genome volume targets would shift the balance.
- Meaningful progress on cash generation by the next update would strengthen the fundamental case.
Coming up
- US: Consumer prices · expected 2.8%, previous 2.6%
- US: Jobless claims
Economic data for WGS
Full calendarComing up
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%in 4h
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%in 4h
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896in 4h
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 4h
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%in 4h
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 4h
- TodayUSDCPI●●●Forecast 338.683Previous 336.298in 4h
- November 12, 2026USDInitial Jobless Claims●●●in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about WGS
Frequently asked questions about GeneDx Holdings
What did GeneDx report for the third quarter?
Revenue came in at $123.1 million, up from $116.7 million a year earlier. Management kept full-year revenue guidance at $475-490 million, quantified adjusted net income at about $12 million and lifted the adjusted gross margin target to roughly 71 percent. The reported net loss nonetheless widened to $12.3 million from $7.6 million.
Why is the verdict neutral rather than positive after rising revenue?
The quarter shows two sides. Revenue and adjusted profitability improved and full-year guidance held, but management cut the exome and genome volume and revenue growth targets, and both the net loss and the operating cash outflow grew. With no price history available to add a technical view, these offsetting forces leave the picture balanced.
What should I watch next for this stock?
Two things stand out. The high-impact US inflation readings due shortly set the market backdrop and could move growth stocks either way if they land far from expectations. Beyond that, whether GeneDx meets or misses its lowered exome and genome volume targets, and any narrowing of the operating cash outflow, would shift the fundamental balance.
📝 Overview Generated automatically
WGS has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Neutral (100%).
Breakdown: 0 bullish, 0 bearish, 1 neutral.
Most-cited catalysts: Full-year 2026 revenue guidance maintained at $475 to $490 million (1×), Adjusted net income guidance quantified at approximately $12 million with adjusted gross margin of approximately 71% (1×). Most-cited risk factors: Exome and genome volume growth guidance cut to at least 28% from at least 30% (1×), Exome and genome revenue growth guidance cut to at least 17% from at least 20% (1×).